Mode
Text Size
Log in / Sign up
Phase 4 N=167 Randomized Double-blind Treatment

Postoperative Pain Management in Patients Undergoing Intramedullary Nail Fixation After Tibia and Femoral Fractures

Femur Fracture · Tibial Fractures

Enrolled (actual)
167
Serious AEs
11.8%
Results posted
Mar 2025
Primary outcome: Primary: 12hrs VAS Pain Scores — 7.6; 7.9; 7.3; 7.2 score on a scale — p=0.215

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
Intravenous ketorolac and oral acetaminophen (Drug); Intravenous morphine and oral oxycodone (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
University of Puerto Rico
Primary completion
Oct 2022

Outcome Measures

OutcomeResultp-value
PRIMARY
12hrs VAS Pain Scores
7.6; 7.9; 7.3; 7.2 0.215
PRIMARY
24hrs VAS Pain Score
4.9; 5.9; 5.4; 5.1 0.041 sig
PRIMARY
36hrs VAS Pain Scores
4.9; 5.63; 5.3; 5.6 0.12
PRIMARY
48hrs VAS Pain Scores
3.6; 4.3; 4.0; 3.4 0.083
PRIMARY
12hrs MME
2.9; 8.5; 2.9; 12.1 0.002 sig
PRIMARY
24hrs MME
9.2; 21.49; 10.4; 28.8 0.002 sig
PRIMARY
36hrs MME
14.1; 29.5; 15.7; 36.6 0.004 sig
PRIMARY
48hrs MME
18.3; 37.2; 20.1; 48.0 0.006 sig
SECONDARY
Hospital Length of Stay
1.9; 2.00; 1.8; 1.9 0.354

Summary

The purpose of this trial is to determine whether oral acetaminophen and intravenous ketorolac are viable alternatives to opioid medication regimens for the pain management of patients with tibial and femoral shaft fractures treated with intramedullary nailing. This study will explore an alternative for opioid medications for patients undergoing intramedullary nailing of tibial and femoral shaft fractures.

Eligibility Criteria

Inclusion Criteria

  • Patients with tibial and femoral shaft fractures
  • Patients undergoing intramedullary nailing
  • Willing to participate in the protocol

Exclusion Criteria

  • Chronic pain disorder (daily use of oral opioids)
  • Allergy or hypersensitivity to non steroid anti-inflammatory drug
  • Impaired renal, cardiac, or hepatic function
  • History of gastrointestinal bleeding or substance abuse
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04761302). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search